Compare Agilysys Inc (AGYS) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilysys Inc vs Cytokinetics Inc — how do they compare? Agilysys Inc trades at $107.52 (market cap $3.00B), while Cytokinetics Inc trades at $76.67 (market cap $10.63B). The key difference: Cytokinetics Inc is far larger — about 3.5× Agilysys Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Agilysys Inc nearer its low. Which is the better fit depends on your goals.
| AGYS | CYTK | |
|---|---|---|
Market Cap | $3.00B | $10.63B |
Sector | Technology | Technology |
52-Week High | $141.12 | $87.26 |
52-Week Low | $62.19 | $34.31 |
Enterprise Value | $2.90B | $10.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilysys (AGYS) trades at $107.35, up 0.35% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with Q1 and Q2 2026 earnings beats, record subscription revenue growth, and improved FY27 guidance. Technical indicators suggest bullish momentum with support at $106 and resistance at $108. The company's hospitality software solutions are gaining traction through partnerships and AI-driven innovation.
Outlook remains positive with 100% analyst buy ratings and $118.33 consensus price target representing 10.2% upside. Key opportunities include subscription revenue growth and Marriott deployment progress, while risks include execution challenges and competitive pressures in the hospitality technology sector.
Cytokinetics (CYTK) trades at $75.64, down 2.39% on the day, amid a bearish technical signal despite a Q2 2026 earnings beat. The stock shows negative profitability with a net income margin of -1,321.12% and a high P/S ratio of 140.65, reflecting significant losses and premium valuation relative to sales. Recent news highlights strong uptake of MYQORZO and UK regulatory approval, supporting commercial momentum.
The outlook is polarized: analyst consensus is strongly bullish with a $111.14 price target, but high cash burn and competitive pressures pose risks. Investment opportunity hinges on MYQORZO's market expansion, while execution and funding needs remain key challenges for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilysys Inc
Agilysys provides enterprise software and SaaS solutions for the hospitality industry. Its products specialize in point-of-sale, property management, and inventory systems for hotels, resorts, and cruise lines.
Read more on AGYS →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
